Eye stroke treatment shows promise but trial halted early
NCT ID NCT04965038
First seen May 22, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This study tested whether giving a clot-busting drug (tenecteplase or alteplase) within 4.5 hours of sudden vision loss from a blocked retinal artery could help restore sight. The trial enrolled 127 people but was stopped early. Researchers hoped to show that early treatment could lead to meaningful vision recovery, similar to how these drugs are used for brain strokes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL RETINAL ARTERY OCCLUSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Tuebingen
Tübingen, 72076, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenecteplase or Alteplase (clot-busting drugs given intravenously)
What this could lead to
If successful, this approach could become a standard emergency treatment to restore vision after an eye stroke.
What could go wrong
The trial was terminated early, so results are limited. Clot-busting drugs also carry a risk of bleeding, which must be weighed against potential benefits.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.